Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232048 | 0.95 | ALDH1A1 (0.49) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL7094090 | 0.95 | MTNR1A (0.53) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL23804013 | 0.90 | MMP3 (0.50) | L3MBTL1NPC1MAPK1HSD17B10TSHR | |
| SCHEMBL15939672 | 0.88 | L3MBTL1 (0.51) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL28335002 | 0.86 | L3MBTL1 (0.50) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL25349904 | 0.85 | APP (0.51) | NPC1MAPK1HSD17B10TSHRUSP2 | |
| SCHEMBL17164056 | 0.83 | DRD2 (0.57) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL15939818 | 0.82 | MTNR1A (0.53) | L3MBTL1NPC1MAPK1HSD17B10TSHR | |
| SCHEMBL20982809 | 0.82 | L3MBTL1 (0.46) | L3MBTL1RECQLNPC1MAPK1HSD17B10 | |
| SCHEMBL9936527 | 0.81 | L3MBTL1 (0.53) | L3MBTL1RECQLNPC1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023140629-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 닥터아이앤비(주) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023101387-A1 | 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY | 연세대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2020085742-A1 | HETEROAROMATIC MACROCYCLIC DERIVATIVES AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-04-30 | — | — | WO | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10144745-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144745-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | L3MBTL1 2063/4885RECQL 4587/4885NPC1 2916/4885 |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | L3MBTL1 2063/4885RECQL 4587/4885NPC1 2916/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | L3MBTL1 857/4885RECQL 1089/4885NPC1 2608/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | L3MBTL1 857/4885RECQL 1089/4885NPC1 2608/4885 |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | L3MBTL1 1027/4885RECQL 326/4885NPC1 1368/4885 |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | L3MBTL1 857/4885RECQL 1089/4885NPC1 2608/4885 |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | L3MBTL1 2063/4885RECQL 4587/4885NPC1 2916/4885 |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | L3MBTL1 2063/4885RECQL 4587/4885NPC1 2916/4885 |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | L3MBTL1 2063/4885RECQL 4587/4885NPC1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.